SCHEMBL3202671

SCHEMBL3202671

O=C1[C@H]2[C@H]3C[C@@H]([C@@H]2C(=O)N1c1cc(Cl)cc(Cl)c1)[C@@H](c1ccccc1)C3

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.58
ALDH1A1 P00352 5/20 0.58
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
ADCY2 Q08462 2/20 0.39
ALOX15 P16050 3/20 0.39
GAA P10253 2/20 0.39
ALOX12 P18054 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 3/20 0.38
KDM1A O60341 1/20 0.37
POLB P06746 2/20 0.36
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3194566 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL13483327 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL6748128 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3194557 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3199298 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL6748131 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3199306 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3202665 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3194553 1.00 MAPK1 (0.58) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3201418 0.86 MAPK1 (0.55) MAPK1ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655688-B2 Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-02 US disclosed
US-20060111424-A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function SALVATI MARK E 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111424-A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function NCOA1, ESRRA, NR5A1 MAPK1 3663/4885ALDH1A1 3191/4885MEN1 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.